Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)

NICE technology appraisals [TA207] Published date:

NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma because no evidence submission was received from the manufacturer or sponsor of the technology.

Get involved